Brief: Nexalin Technology Advances Clinical Trial Of HALO Clarity Toward Q2 2026 Enrollment
22/04/2026 16:17
April 22 (Reuters) - Nexalin Technology Inc NXL.O: NEXALIN TECHNOLOGY ADVANCES PIVOTAL CLINICAL TRIAL OF HALO™ CLARITY TOWARD Q2 2026 ENROLLMENT NEXALIN TECHNOLOGY: PATIENT ENROLLMENT CURRENTLY EXPECTED TO BEGIN IN Q2 OF 2026 Source text: ID:nGNX4gQb34 Further company coverage: NXL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalin Technology
See all newsBrief: Nexalin Technology Regains Compliance With Nasdaq Minimum Bid Price Requirement Nasdaq Hearings Panel Grants Request For Continued Listing
NASDAQ RESUMED AT 12:48 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:43 PM
NASDAQ RESUMED AT 10:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:24 AM